February 16, 2018 09:44 AM EST
News Briefing

Roivant Sci­ences in ex­clu­sive joint ven­ture talks with Ar­bu­tus; DBV gets green light to sub­mit peanut al­ler­gy patch

Amber Tong

→ Months af­ter in­vest­ing $116 mil­lion in­to Cana­da’s Ar­bu­tus $ABUS, Roivant Sci­ences con­firmed ear­ly spec­u­la­tions that it’s ex­plor­ing a joint ven­ture deal. The com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times